Emergent BioSolutions grants RSUs to CFO

Emergent BioSolutions reported that EVP and Chief Financial Officer Richard S. Lindahl acquired 162,680 shares of common stock through a restricted stock unit grant at no cash cost.

Rhea-AI Filing Summary

Emergent BioSolutions reported that EVP and Chief Financial Officer Richard S. Lindahl acquired 162,680 shares of common stock through a restricted stock unit grant at no cash cost. The grant was approved by the Compensation Committee on March 2, 2026, and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, contingent on continued service. Following this award, Lindahl directly holds 378,047 shares of Emergent BioSolutions common stock.

Insider Trade Summary

Grant/Award: 162,680 shares

Grant/Award 1 txn

Insider LINDAHL RICHARD S

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	162,680	$0.00	$0.00

Holdings After Transaction: Common Stock — 378,047 shares (Direct)

Footnotes (2)

1. F1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
2. F2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Key Figures

RSU grant size: 162,680 shares Transaction price: $0.0000 per share Post-transaction holdings: 378,047 shares +3 more

6 metrics

RSU grant size 162,680 shares Restricted stock units granted to CFO on March 2, 2026

Transaction price $0.0000 per share Reported price per share for the RSU acquisition

Post-transaction holdings 378,047 shares CFO’s direct Emergent BioSolutions common stock after grant

Plan approval date April 29, 2026 Stockholders approved the Amended Stock Incentive Plan

Grant approval date March 2, 2026 Compensation Committee approved the restricted stock unit grant

Vesting schedule Three annual installments RSUs vest annually starting on the approval anniversary

Key Terms

restricted stock units, Amended Stock Incentive Plan, Compensation Committee

3 terms

restricted stock units financial

"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended Stock Incentive Plan financial

"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")"

Compensation Committee financial

"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Emergent BioSolutions (EBS) disclose for its CFO?

Emergent BioSolutions disclosed that its EVP and Chief Financial Officer, Richard S. Lindahl, received 162,680 restricted stock units. The award represents equity compensation rather than an open-market purchase and increases his direct holdings of Emergent common stock to a total of 378,047 shares.

How many Emergent BioSolutions (EBS) shares did the CFO hold after the Form 4 transaction?

After the reported grant, Emergent BioSolutions CFO Richard S. Lindahl directly held 378,047 shares of common stock. This total includes the newly awarded 162,680 restricted stock units, which convert into shares as they vest over the three annual installments described in the grant.

Was cash paid for the Emergent BioSolutions (EBS) CFO’s new shares on this Form 4?

No cash was paid for these shares; the transaction price per share was reported as 0.0000. The 162,680 shares were granted as restricted stock units under Emergent BioSolutions’ Amended Stock Incentive Plan, reflecting equity-based compensation rather than a market purchase.

What plan governs the Emergent BioSolutions (EBS) CFO’s restricted stock unit grant?

The restricted stock unit grant to the Emergent BioSolutions CFO was made under the company’s Amended Stock Incentive Plan. Stockholders approved this amended plan on April 29, 2026, following prior approval of the grant terms by the board’s Compensation Committee on March 2, 2026.

How do the Emergent BioSolutions (EBS) CFO’s restricted stock units vest over time?

The 162,680 restricted stock units granted to the Emergent BioSolutions CFO vest in three equal annual installments. Vesting begins on the anniversary of the grant’s approval date and is conditioned on his continued service with the company throughout each applicable vesting period.

What does each restricted stock unit represent for Emergent BioSolutions (EBS) CFO?

Each restricted stock unit granted to the Emergent BioSolutions CFO represents the right to receive one share of Emergent common stock. Delivery occurs as units vest, subject to the terms and potential adjustments described in the grant agreement under the Amended Stock Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026	04/29/2026(1)	A		162,680(2)	A	$0	378,047	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)